RaySearch delivers incredibly strong results with record sales, a 96% gross margin, and an EBIT marg...
Redeye comments on Medivir’s Q2 report. A rights issue of cSEK150m was announced, which will fund a ...
Nanexa’s Q3 report underscores a pivotal moment for the company.
* Sales in line, EBIT adj. EUR +0.5m vs. ABGSCe * Orders -18% vs.
Absolent’s third quarter showed sequential improvement, although sales and margins were still down Y...
Redeye provides an update following Optomed’s Q3 2025 report.
Redeye adjusts its estimates and fair value range following Arise’s Q3 report.
We lower our group gross margin assumptions by 70bp for 2025 and 20-30bp for 2026-27, predominantly ...
Redeye retains its positive view of Transtema, despite a soft Q3 report, which shows further decline...
* Uneventful Q3, but big financing news after the quarter * Equity raise at SEK 19/share, 5pp less d...
* We trim EBIT by 4-3% on slightly lower margins * Strong growth continues, with impressive margin r...
SynAct Pharma is focused on inflammation resolution therapeutics.
Administer’s Q3 was soft, with lower net sales weighing on profitability.
Redeye considers Arise’s Q3 2025 report to be largely in line with estimates when adjusting for one-...
* Reports Q3 in line with pre-announced figures * Seasonally weaker quarter, but 17% organic growth ...
